louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06187883: Pulsed Radiofrequency of Lateral Femoral Cutaneous Nerve
Official title: Does Obesity EffectThe Successful Response to the Pulsed Radiofrequency of Lateral Femoral Cutaneous Nerve in Meralgia Parestetica? : A Retrospective Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Meralgia Paresthetica
Keywords: meralgia parestetica
pulsed radiofrequency
obesity
dn4
neuropathic pain
Lead sponsor: Mersin Training and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2024-01-03
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients older than 18 years treated with PRF neuromodulation of LFCN for MP and followed up at least 6 months in the pain clinic of the tertiary hospital between January 2020 and August 2023.

Brief summary: In the current retrospective cohort study, conducted by both pain specialists and neurophysiologists, the primary outcome was to search for the effect of obesity on the efficacy of PRF of LFCN in refractory MP for 6 months. Secondary outcomes were to identify the clinical and diagnostic features of the MP.

Detailed description: In the current retrospective cohort study, conducted by both pain specialists and neurophysiologists, the primary outcome was to search for the effect of obesity on the efficacy of PRF of LFCN in refractory MP for 6 months. Secondary outcomes were to identify the clinical and diagnostic features of the MP.

Eligibility criteria: Inclusion Criteria:

* older than 18 years treated with PRF neuromodulation of LFCN for MP
* followed up at least 6 months in the pain clinic of the tertiary hospital between January 2020 and August 2023.

Exclusion Criteria:

* inadequate follow-up or missing documentation
* If a new analgesic drug was prescribed during the follow-up period that could affect the evaluation of outcomes, the patients were also excluded.
* Patients who missed appointments, or were unable to communicate with; were not included in the study.
* Patients with secondary entrapment neuropathy (e.g., diabetes, inflammatory arthritis, hypothyroidism), malignancy, pregnancy, skin infection in the inguinal region or dermatitis, lumbar radiculopathy, polyneuropathy, and cardiac pacemakers were excluded.
* In the SSEP analysis, when the latency of LFCN was not evaluated in both sides, these patients were not also included in the study.

Primary outcomes:
measure: response to PRF
timeFrame: 6 months
Secondary outcomes:
measure: Secondary outcomes were to identify the clinical and diagnostic features of the MP
timeFrame: 6 months
Other outcomes:
Locations:
city: Mersin
country: Turkey
facility: Suna Aşkın Turan
Study officials:
affiliation: Mersin Şehir Hastanesi
name: Aşkın Turan, MD
role: STUDY_CHAIR
References:
Clinical trial NCT00322283: Study of Oglemilast for the Prevention of Asthma.
Official title: Efficacy and Safety of Oglemilast in the Prevention of Exercise-Induced Bronchospasm
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Exercise-Induced Asthma
Keywords: oglemilast
asthma
exercise
prevention
prophylaxis
Lead sponsor: Forest Laboratories
Sponsor class: INDUSTRY
First posted: 2006-05-05
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine whether it is effective in the treatment of exercise-induced asthma and investigate the safety of oglemilast.


Eligibility criteria: Inclusion Criteria:

* stable mild asthma patients who exhibit at least a 20% decrease in FEV1 following exercise.

Exclusion Criteria:

* pulmonary disease other than asthma, psychiatric illness, active cardiac disease, high blood pressure, history of substance abuse, current smokers.

Primary outcomes:
measure: To determine the efficacy of oglemilast as compared to placebo in preventing exercise-induced asthma following 15 days of treatment.
Secondary outcomes:
measure: To evaluate the safety of oglemilast over 2 weeks as determined by adverse events, physical examinations, vital signs, electrocardiograms, and laboratory examinations.
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Forest Investigative Site
state: California
city: N. Dartmouth
country: United States
facility: Forest Investigative Site
state: Massachusetts
Study officials:
References:
Clinical trial NCT01368783: Two Clinical Trials to Evaluate Pharmacokinetics of Unboosted and Boosted Atazanavir Used Alone or Co-administered With Tenofovir DF in Healthy Korean and Caucasian Male Volunteers
Official title: Two Randomized, Open-labeled, Parallel Designed Multiple-dose Clinical Trials to Evaluate Pharmacokinetics of Ritonavir-unboosted and Ritonavir-boosted Atazanavir Used Alone or Co-administered With Tenofovir DF in Healthy Korean and Caucasian Male Volunteers
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Atazanavir
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
Collaborators: name: Bristol-Myers Squibb
First posted: 2011-06-08
Enrollment: 32
Sex: MALE
Minimum age (years): 20
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Compared to those of Caucasians, the plasma levels of atazanavir (ATV) may be higher in Koreans with the same dosage regimen(s). If so, even unboosted ATV could be used with tenofovir DF (TDF) which lowers the concentration of ATV. The investigators plan to investigate the pharmacokinetic features of ATV with or without TDF in healthy Korean and Caucasian volunteers and compare the ethnic differences.


Eligibility criteria: Inclusion Criteria:

* Men aged 20 to 55 years old, with a weight more than 50 kg and with appropriate body mass index (BMI) values within 19-28 kg/m2.
* Agreed voluntarily to participate to the study and comply with the study protocol with written permission.

Exclusion Criteria:

* Has history of liver, kidney, respiratory, musculoskeletal, endocrinologic, neuropsychiatric, hemato-oncologic, or cardiovascular problem(s).
* Has history of hypersensitivity or clinically significant adverse drug reaction(s) to the study drugs, same class of the study drugs, or other drugs including aspirin and antibiotics.
* Drinks excessive caffeinated beverages (caffeine \>10 units/day), alcohol beverages (alcohol \>21 units/week) or smokes excessively (\>20 cigarettes/day) or has history of alcoholism.
* Has been excluded by the researchers due to abnormal findings in screening EKG and/or blood tests

Primary outcomes:
measure: Pharmacokinetic analysis
Secondary outcomes:
measure: Pharmacokinetic evaluation
Other outcomes:
Locations:
city: Songpa-gu
country: Korea, Republic of
facility: Asan Medical Center
state: Seoul
Study officials:
References:
Clinical trial NCT02078583: The Effect of Analgesia Based Sedation Protocol on Brain Function of Critical Care Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Delirium
Lead sponsor: Peking University People's Hospital
Sponsor class: OTHER
First posted: 2014-03-05
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Benzodiazepines is a commonly uesd sedative medication,there are many reports that Benzodiazepines is associated with delirium ,but using of analgesia reduces benzodiazepines requirements .The purpose of this study is to determine whether analgesia based sedation protocol reduces the incident of delirium.


Eligibility criteria: Inclusion Criteria:

* Signing a consent form
* postoperative patient
* Requirement for mechanical ventilation and anticipate time of mechanical ventilation more than 24 hours
* Requirement for sedation
* Age more than 18 and less than 85 years old

Exclusion Criteria:

* Unstable blood circulation
* Heart rate less than 50 beats per minute
* II ° ～ III ° atrioventricular conduct block
* Intracranial lesions 、neurosurgical intervention and mental disability inability to cooperate;
* Receipt of antipsychotics 、hypnotic drugs before surgery ;
* Alcohol abuse;
* Liver failure class Child-Pugh C;
* Acute Respiratory Distress Syndrome;
* Acute or chronic renal failure;
* Other severe diseases ,septic shock;
* Receipt of neuromuscular blocking drug;
* Pregnancy and nursing woman;
* Allergy to investigational drug or other contraindication.

Primary outcomes:
measure: The incidence and duration of delirium in patients with different regimens
timeFrame: 1 day
Secondary outcomes:
measure: Mortality
timeFrame: 28 days
measure: Ventilator-free days
timeFrame: an expected average of 7 days
measure: Mean days of mechanical ventilation
timeFrame: an expected average of 7 days
measure: Length of ICU stay
timeFrame: an expected average of 7 days
measure: Index of anesthesia depth monitoring
timeFrame: From admission to ICU to weaning,about 7 days
measure: Infusion velocity and total dose of sedative drugs in different groups
timeFrame: From admission to ICU to extubation or drug withdrawal,about 7 days
measure: Plasma melatonin level
timeFrame: Every 6 hours during the next ICU day
measure: Total rescue dose of midazolam
timeFrame: Seven days after giving midazolam to patient
measure: Variations of HR、RR、BP、SpO2
timeFrame: an expected average of 7 days
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04028583: Tool for Inappropriate Prescription Evaluation: The TaIPE Study
Official title: Tool for Inappropriate Prescription Evaluation: The TaIPE Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Inappropriate Prescribing
Keywords: Inappropriate Prescribing
Potentially Inappropriate Medication List
Aged
Practice Guideline
Education, Medical
Lead sponsor: Centre Hospitalier Universitaire Vaudois
Sponsor class: OTHER
First posted: 2019-07-22
Enrollment: 464
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A mono-center, randomized controlled trial will be conducted at the University Hospital of Lausanne. Hospitalized patients will be randomly assigned from the emergency department to two sub-units composing the acute care for elders (ACE) unit. In one subunit, potentially inappropriate prescriptions will be detected and treatment optimized according PIM-Check. In the other, STOPP/START criteria will be independently applied.


Eligibility criteria: Inclusion Criteria:

* All patients meeting the admission criteria of the acute care for elders (ACE) unit will be eligible.

Exclusion Criteria:

* none

Primary outcomes:
measure: Rate of Potentially Inappropriate Prescriptions (PIPs) reduction in the PIM-Check group compared to STOPP/START
timeFrame: 18 months
Secondary outcomes:
measure: Number and type of PIPs detected by each tool
timeFrame: 18 months
measure: Rate of acceptability
timeFrame: 18 months
measure: Number of treatment (mean and median) modification by clinicians
timeFrame: 18 months
measure: Number of drugs at discharge
timeFrame: 18 months
measure: Incidence rate of falls
timeFrame: 18 months
measure: Activities of daily living (ADL) score
timeFrame: 18 months
measure: Confusion Assessment Method (CAM)
timeFrame: 18 months
measure: Length of stay
timeFrame: 18 months
measure: Number of unplanned readmission
timeFrame: up to 3 months after discharge
measure: Association between the number and type of PIPs at discharge with rate of re-admission
timeFrame: up to 3 months after discharge
Other outcomes:
Locations:
city: Lausanne
country: Switzerland
facility: Centre Hospitalier Universitaire Vaudois
state: Vaud
Study officials:
References:
citation: Farhat A, Al-Hajje A, Lang PO, Csajka C. Impact of Pharmaceutical Interventions with STOPP/START and PIM-Check in Older Hospitalized Patients: A Randomized Controlled Trial. Drugs Aging. 2022 Nov;39(11):899-910. doi: 10.1007/s40266-022-00974-7. Epub 2022 Sep 30.
Clinical trial NCT00266383: The Molecular Mechanism and the Role of NRAMP 1gene on Tuberculosis in Taiwan Aboriginal Tribes Population
Official title: The Molecular Mechanism and the Role of NRAMP 1gene on Tuberculosis in Taiwan Aboriginal Tribes Population
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Tuberculosis
Lead sponsor: National Health Research Institutes, Taiwan
Sponsor class: OTHER
First posted: 2005-12-16
Enrollment: 250
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: OTHER

Brief summary: The human homologue of mice natural-resistance-associated macrophage protein 1 (Nramp 1) gene, NRAMP 1, has been reported to play a role in the susceptibility to tuberculosis in humans. The aboriginal population in Taiwan has a 5-fold higher prevalence of tuberculosis than the Han Chinese. Whether genetic factors such as NRAMP 1 polymorphisms play a role in the prevalence of tuberculosis in Taiwanese aboriginals should be clarified.


Eligibility criteria: Inclusion Criteria:

* The NRAMP 1 polymorphism of tuberculous patients in Taiwan.

Exclusion Criteria:

-

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Miaoli county
country: Taiwan
facility: National Health Research Institutes
Study officials:
affiliation: Division of Clinical Research, National Health Research Institutes
name: Ih-Jen Su, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03502083: Human Vasodilatory Effect of GLP-1
Official title: Vasodilatory Effect of GLP-1
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Coronary Stenosis
Type2 Diabetes
Angina, Stable
Lead sponsor: Papworth Hospital NHS Foundation Trust
Sponsor class: OTHER_GOV
First posted: 2018-04-18
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Comprehensive assessment of human vasodilatory effect of GLP-1 in forearm and coronary arteries


Eligibility criteria: Inclusion Criteria:

* Waiting list for elective PCI to LAD Able to give informed consent Over 18

Exclusion Criteria:

* GLP-1 based therapy Insulin Calcium channel blockers Nicorandil Nitrates

Primary outcomes:
measure: Change in IMR (index of microcirculatory resistance) with GLP-1 compared with baseline
timeFrame: Change from baseline
measure: Forearm bloodflow ratio with GLP-1
timeFrame: Change from baseline
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Aetesam-Ur-Rahman M, Zhao TX, Paques K, Oliveira J, Khialani B, Kyranis S, Braganza DM, Clarke SC, Bennett MR, West NEJ, Hoole SP. Coronary Flow Variations Following Percutaneous Coronary Intervention Affect Diastolic Nonhyperemic Pressure Ratios More Than the Whole Cycle Ratios. J Am Heart Assoc. 2022 May 3;11(9):e023554. doi: 10.1161/JAHA.121.023554. Epub 2022 Apr 26.
citation: Aetesam-Ur-Rahman M, Giblett JP, Khialani B, Kyranis S, Clarke SJ, Zhao TX, Braganza DM, Clarke SC, West NEJ, Bennett MR, Hoole SP. GLP-1 vasodilatation in humans with coronary artery disease is not adenosine mediated. BMC Cardiovasc Disord. 2021 May 1;21(1):223. doi: 10.1186/s12872-021-02030-5.
Clinical trial NCT06189183: Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection
Official title: Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection-Single Center Phase II Single Arm Clinical Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Thymus Neoplasms
Keywords: Thymus Neoplasms
Adjuvant Radiotherapy
Lead sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Sponsor class: OTHER
First posted: 2024-01-03
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficiency and toxicity of adjuvant hypofractionation radiotherapy for thymic epithelial tumours after complete resection.

Detailed description: Adjuvant Radiotherapy(Postoperative radiotherapy) is proposed in stage II and III thymic carcinoma，stage III thymoma，stage IIB B2/B3 thymomas.

Hypofractionation Radiotherapy is used in this study. The purpose of this study is to evaluate the efficiency and toxicity of adjuvant hypofractionation radiotherapy for thymic epithelial tumours after complete resection.

Eligibility criteria: Inclusion Criteria:

* Thymoma and Thymic carcinoma confirmed by histology or cytology
* R0 resection (complete resection)
* stage II and III thymic carcinoma，stage III thymoma，stage IIB B2/B3 thymomas.
* Karnofsky performance status(KPS) 80, 90 or 100.
* Having sufficient Pulmonary function, renal function and liver function. Neutrophile granulocyte count\>1.5×109 /L, platelet count\>80×109 /L, hemoglobin ≥10g/dL.

Exclusion Criteria:

* Prior thoracic radiotherapy.
* Uncontrolled Comorbidities.
* Pregnant or nursing mother.
* Pneumonia

Primary outcomes:
measure: Disease Free Survival
timeFrame: 2 years, 5 years
Secondary outcomes:
measure: Overall Survival
timeFrame: 2 years, 5 years
measure: RadiotherapyToxicity
timeFrame: 1 years, 2 years, 5 years
measure: local recurrence
timeFrame: 2 years, 5 years
measure: Intrathoracic recurrence / pleural metastasis
timeFrame: 2 years, 5 years
measure: metastasis free survival
timeFrame: 2 years, 5 years
Other outcomes:
Locations:
city: Beijing
country: China
facility: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College
state: Beijing
Study officials:
affiliation: National Cancer Center/Cancer Hospital, CAMS
name: Tao Zhang, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06506383: Coronary Artery Disease Mortality in Turkiye
Official title: Geographical Variations and Predictors of Coronary Artery Disease Mortality in Turkiye: An Environmental and Behavioral Analysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Disease (CAD) Mortality
Lead sponsor: Medipol University
Sponsor class: OTHER
First posted: 2024-07-17
Enrollment: 81
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population includes all citizens in each of the 81 provinces of Turkiye

Brief summary: This study aims to analyze the geographical variations and identify key environmental and behavioral predictors of coronary artery disease (CAD) mortality in Turkiye.

Detailed description: A 10-year longitudinal province-level data was used to identify change trajectories of CAD mortality. . Environmental determinants (such as air quality and climatic conditions) and behavioral factors of alcohol consumption and smoking were examined for their association with CAD mortality change trajectories using Ordinal Logistic Regression models.

Eligibility criteria: Inclusion Criteria:

* All citizens in a given province

Exclusion Criteria:

* None

Primary outcomes:
measure: CAD Mortality
timeFrame: 2010-2019
Secondary outcomes:
Other outcomes:
Locations:
city: Beykoz
country: Turkey
facility: Istanbul Medipol University
state: Istanbul
Study officials:
References:
Clinical trial NCT00041483: Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD
Official title: Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Macular Degeneration
Keywords: AMD
age-related macular degeneration
Anecortave
Acetate
Wet form of age-related macular degeneration
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2002-08-01
Enrollment: 530
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to demonstrate that Anecortave Acetate is as effective after twelve months of treatment as photodynamic therapy (PDT) with Visudyne in patients eligible for initial PDT treatment for wet age-related macular degeneration.


Eligibility criteria: Patients of any race, either gender, aged 50 years and above, diagnosed with subfoveal CNV due to AMD with best corrected logMAR visual acuity of 20/40 (snellen equivalent) to 20/400 (Snellen equivalent) in the study eye. Clinically relevant concomitant diseases will be excluded.

Primary outcomes:
measure: Percentage of Patients Maintaining Vision
timeFrame: Month 12
Secondary outcomes:
Other outcomes:
Locations:
city: Ft. Worth
country: United States
facility: Contact Alcon Call Center for Trial Locations
state: Texas
Study officials:
References: